This premier B2B event provides the appropriate platform to engage and discuss ideas with your peers, while facilitating a professional atmosphere and environment for good company representation and development.
The Summit will shed light on current challenges, best practices and the inside view of the future of Antibodies.
We will discuss key findings, including critical insights, as well as recommendations for driving efficient strategies in the Antibodies.
Key Practical Learning Points of the Summit:
Who Should Attend:
Chief Executives, Vice Presidents, Directors, Department Heads, Leaders, Managers, Clinical Development Experts and Scientists specialising in
Dr. Martin Steegmaier Head of Discovery & Site Head Large Molecule Research Pharma Research & Early Development (pRED) Roche Diagnostics GmbH, Germany
Dr. Eric Valeur Associate Director New Modalities & Lead Generation AstraZeneca, Sweden
Dr. Brian Fennell BioMedicine Design (BMD) Pfizer, Ireland
Dr. Marina Feschenko Principle Scientist Biogen, US
Dr. Jürgen Schäfer Mass Spectrometry Lab Head R&D / Pharmaceutics Development Platform / Analytical Sciences Frankfurt Sanofi-Aventis Deutschland GmbH, Germany
Dr. Kay-Gunnar Stubenrauch Sr. Principal Scientist Pharmaceutical Sciences Division of pRED (Pharma Research & Early Development) Roche Innovation Center Munich, Germany
Dr. Anke Steinmetz Senior Researcher Sanofi, France
Dr. Ulrich Rümenapp Head of Launch Preparation & Coordination Bayer Pharma AG, Germany
Please, complete details below:
Please, complete details below and you will get Agenda via E-mail:
Please, complete details below and you will get 500 € Document Package: